Roxadustat's Effect on Heart, Nutrition, and Inflammation in Hemodialysis Patients
Recruiting
Phase 1
Phase 2
Interventional Study
Kidney Failure, Chronic
Malnutrition-Inflammation Syndrome
Anemia in End Stage Renal Disease
Cardiovascular Diseases (CVD)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 1/2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 46 (estimated)
- Sponsor
- Mansoura University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Patients with kidney failure who require hemodialysis often suffer from anemia (low red blood cell count), heart and blood vessel problems, and a condition involving poor nutrition, inflammation, and hardening of the arteries (called MIA syndrome). Standard treatments for anemia often involve injections and iron supplements. This study aims to see if a newer oral medication, Roxadustat, works bett…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Age of patient is more than 18.
* Patients who are willing to sign informed consent.
* Patients with ESKD on chronic hemodialysis for more than 3 months.
Exclusion Criteria:
* Current pregnancy or lactation.
* Patients with pre-existing malignancy.
* Patients with psychosis …
Contacts